Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound   Target Concepts: Gene/Protein Disease Symptom Drug Enzyme Compound

---

Query: EC:3.1.1.53 (sialidase)
2,694 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We have determined the concentration effects of feeding for 8 weeks 10.8%, 21.6%, and 36% dietary ethanol calories on the activities and relative synthetic rates (RSRs) of various subcellular sialidases of rat liver. The hepatic RSRs of each species of sialidase was determined based on the ratio of 1-hour incorporation of [35S]-methionine into immunoprecipitable sialidase as percent of the incorporation into total protein in each subcellular fraction. Ganglioside sialidase activities in the hepatic subcellular fractions were also determined. Ethanol feeding at 36% dietary calories caused an increase in the ganglioside sialidase activity of the plasma membrane sialidase (PMS) by 232% (P < .01) and that of cytosolic sialidase (CS) by 184% (P < .05), but decreased the lysosomal membrane sialidase (LMS) by 54% (P < .01) when compared with the control animals. The specificity of each antisialidase antibody was verified by immunoblots. The RSR of PMS was increased by 40% (P < .01), 67% (P < .01), and 220% (P < .01) in the 10.8%, 21.6%, and 36% ethanol groups, respectively. Similarly, the RSR of CS was increased by 17% (P < .01), 19% (P < .01), and 63% (P < .01), respectively, in these ethanol groups. In contrast, the RSR of LMS was inhibited by 36% (P < .01), 34% (P < .01), and 69% (P < .01), respectively, in these ethanol groups. Intralysosomal sialidase failed to hydrolyze gangliosides. Thus, PMS and CS, but not LMS or intralysosomal sialidase, may play important roles in ethanol-modulated desialylation of gangliosides and consequent liver injury and behavioral alterations.
...
PMID:Chronic ethanol feeding controls the activities of various sialidases by regulating their relative synthetic rates in the rat liver. 1609 56

We have previously shown that chronic ethanol feeding stimulates liver cytosolic sialidase (CS) and plasma membrane sialidase (PMS), whereas it decreases lysosomal membrane sialidase (LMS) activities with concomitant alterations in their relative synthetic rate in rat. To understand the molecular mechanism(s) for these changes, we have evaluated the effect of ethanol administration in male Wistar rats as a function of increasing dietary ethanol concentration after 8 weeks of pair-feeding on (i) the expression of CS, PMS, and LMS genes by real-time quantitative polymerase chain reaction method; (ii) their relative transcription rates by nuclear run-on assay; and (iii) the actual amount of these sialidase proteins in the liver fractions of the respective groups by Western blot method. We have demonstrated that the animals fed with 10.6%, 20.8%, and 36% of total calories as ethanol showed a 20% (P<.05), 34% (P<.01), and 69% (P<.01) increase in CS mRNA level, and 22% (P<.05), 26% (P<.01), and 47% (P<.01) increase in PMS mRNA level, but a decrease in LMS mRNA level by 35% (P<.05), 50% (P<.01), and 80% (P<.01), respectively, as compared to controls. Western blot analyses of CS, PMS, and LMS in the liver subfractions showed that changes in protein levels of CS, LMS, and PMS were consistent with the corresponding changes in the respective mRNA levels. Thus, the upregulation of CS and PMS, but not LMS which is down regulated by chronic ethanol, may account for the appearance of asialoconjugates in alcoholics.
...
PMID:Chronic ethanol consumption upregulates the cytosolic and plasma membrane sialidase genes, but down regulates lysosomal membrane sialidase gene in rat liver. 1671 41

The use of oseltamivir, widely stockpiled as one of the drugs for use in a possible avian influenza pandemic, has been reported to be associated with neuropsychiatric disorders and severe skin reactions, primarily in Japan. Here we identified a nonsynonymous SNP (single nucleotide polymorphism) in dbSNP database, R41Q, near the enzymatic active site of human cytosolic sialidase, a homologue of virus neuraminidase that is the target of oseltamivir. This SNP occurred in 9.29% of Asian population and none of European and African American population. Our structural analyses and Ki measurements using in vitro sialidase assays indicated that this SNP could increase the unintended binding affinity of human sialidase to oseltamivir carboxylate, the active form of oseltamivir, thus reducing sialidase activity. In addition, this SNP itself results in an enzyme with an intrinsically lower sialidase activity, as shown by its increased Km and decreased Vmax values. Theoretically administration of oseltamivir to people with this SNP might further reduce their sialidase activity. We note the similarity between the reported neuropsychiatric side effects of oseltamivir and the known symptoms of human sialidase-related disorders. We propose that this Asian-enriched sialidase variation caused by the SNP, likely in homozygous form, may be associated with certain severe adverse reactions to oseltamivir.
...
PMID:A nonsynonymous SNP in human cytosolic sialidase in a small Asian population results in reduced enzyme activity: potential link with severe adverse reactions to oseltamivir. 1743 75

Cell surface carbohydrate expression strongly influences the biological characteristics of cancer cells. Especially, it is known that the change of sialic acid expression could be related to the invasive and metastatic potentials of tumors. This study aimed to investigate sialidase expression of ovarian cancer cells and to evaluate the relationship between plasma membrane-associated sialidase (NEU3) expression and various clinicopathological factors in ovarian clear cell adenocarcinoma patients. In 18 cell lines derived from human ovarian cancers (including clear cell, mucinous, and serous adenocarcinoma), sialidase mRNA expression was evaluated by RT-PCR. NEU1 and NEU3 expression levels were found to be elevated in most cell lines while NEU2 and NEU4 expression was rarely elevated. Interestingly, NEU3 expression was detected in all clear cell adenocarcinoma cell lines. In 71 patients with ovarian clear cell adenocarcinoma, treated at Keio University Hospital from February 1983 to February 2002, NEU3 expression was examined by immunohistochemical staining of surgical specimens and clinicopathological factors were reviewed. NEU3 expression was found to be positive in 77.5% of all cases. Furthermore, a high level of NEU3 expression was significantly correlated with T3 factor of pTNM classification on univariate and multivariate analysis. This is the first report to show that NEU3 is expressed in most of ovarian clear cell adenocarcinoma. And our results show that NEU3 expression is correlated with T factor (pTNM classification) in ovarian clear cell adenocarcinoma.
...
PMID:Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification. 1747 74

Oseltamivir (Tamiflu) and zanamivir (Relenza), two extensively used clinically effective anti-influenza drugs, are viral sialidase (also known as neuraminidase) inhibitors that prevent the release of progeny virions and thereby limit the spread of infection. Recently mortalities and neuropsychiatric events have been reported with the use of oseltamivir, especially in pediatric cases in Japan, suggesting that these drugs might also inhibit endogenous enzymes involved in sialic acid metabolism, including sialidase, sialyltransferase, and CMP-synthase, in addition to their inhibitory effects on the viral sialidase. The possible inhibition could account for some of the rare side effects of oseltamivir. However, there has been little direct evidence in regard to the sensitivities of animal sialidases to these drugs. Here, we examined whether these inhibitors might indeed affect the activities of human sialidases, which differ in primary structures and enzyme properties but possess tertiary structures similar to those of the viral enzymes. Using recombinant enzymes corresponding to the four human sialidases identified so far, we found that oseltamivir carboxylate scarcely affected the activities of any of the sialidases, even at 1 mM, while zanamivir significantly inhibited the human sialidases NEU3 and NEU2 in the micromolar range (K(i), 3.7 +/- 0.48 and 12.9 +/- 0.07 microM, respectively), providing a contrast to the low nanomolar concentrations at which these drugs block the activity of the viral sialidases.
...
PMID:Limited inhibitory effects of oseltamivir and zanamivir on human sialidases. 1869 48

Recent advances in the sialidase biology have clarified the role of human sialidases (NEU 1 to NEU4) in the development of various disease states such as cancer, diabetes and arteriosclerosis. Isoform selective human sialidase inhibitors could be a therapeutic tool or molecular probes for the exploration of the specific functions of human sialidases. In the present study, de novo design based virtual screening was performed to find a new class of human sialidase inhibitors using the experimental crystal structure of NEU2 isoform. A few of nitro benzene and fluoro benzoic acid were identified and a series of 4-acetamido-5-acylamido-2-fluoro benzoic acids were synthesized and, the inhibitory activity of all these compounds against all human sialidase enzymes was evaluated. All these compounds were found to have a poor inhibitory activity and only NEU2 showed more sensitivity to this series of compounds as compared to other isoforms. Molecular docking was performed to gain insight regarding the binding mode of these inhibitors and thereby provided valuable information for our study on the design of selective human sialidase inhibitors further.
...
PMID:Human sialidase inhibitors: design, synthesis, and biological evaluation of 4-acetamido-5-acylamido-2-fluoro benzoic acids. 1945 Sep 82

A public web server performing computational titration at the active site in a protein-ligand complex has been implemented. This calculation is based on the Hydropathic interaction noncovalent force field. From 3D coordinate data for the protein, ligand and bridging waters (if available), the server predicts the best combination of protonation states for each ionizable residue and/or ligand functional group as well as the Gibbs free energy of binding for the ionization-optimized protein-ligand complex. The 3D structure for the modified molecules is available as output. In addition, a graph depicting how this energy changes with acidity, i.e., as a function of added protons, can be obtained. This data may prove to be of use in preparing models for virtual screening and molecular docking. A few illustrative examples are presented. In beta secretase (2va7) computational titration flipped the amide groups of Gln12 and Asn37 and protonated a ligand amine yielding an improvement of 6.37 kcal mol(-1) in the protein-ligand binding score. Protonation of Glu139 in mutant HIV-1 reverse transcriptase (2opq) allows a water bridge between the protein and inhibitor that increases the protein-ligand interaction score by 0.16 kcal mol(-1). In human sialidase NEU2 complexed with an isobutyl ether mimetic inhibitor (2f11) computational titration suggested that protonating Glu218, deprotonating Arg237, flipping the amide bond on Tyr334, and optimizing the positions of several other polar protons would increase the protein-ligand interaction score by 0.71 kcal mol(-1).
...
PMID:Web application for studying the free energy of binding and protonation states of protein-ligand complexes based on HINT. 1955 65

With the global spread of the pandemic H1N1 and the ongoing pandemic potential of the H5N1 subtype, the influenza virus represents one of the most alarming viruses spreading worldwide. The influenza virus sialidase is an effective drug target, and a number of inhibitors are clinically effective against the virus (zanamivir, oseltamivir, peramivir). Here we report structural and biochemical studies of the human cytosolic sialidase Neu2 with influenza virus sialidase-targeting drugs and related compounds.
...
PMID:Complexity in influenza virus targeted drug design: interaction with human sialidases. 2022 14

The nature and developmental profile of the soluble sialidase of rat forebrain were studied from birth to 150 days. Forebrain was extracted by two procedures, one (mild) preserving, the other (drastic) destroying nerve endings. The soluble extracts obtained by the mild procedure contained 64-78% of the total tissue cytosol, assayed as lactate-dehydrogenase; those obtained by the drastic procedure 87-94%. These latter extracts were considered as the soluble fraction containing 'all' tissue cytosol. The cytosolic origin of the sialidase contained in the soluble extracts at all examined ages was suggested by the following evidence: (a) during extraction sialidase behaved as lactate-dehydrogenase and quite differently from ?-hexosaminidase and ?-galactosidase, enzymes of lysosomal nature present in the same extracts, (b) the sialidase content of the extract was not influenced by the presence or absence of EDTA in the medium, (c) the sialidase content in the extracts did not diminish even after prolonged centrifugation (2 h) at high speed (150,000 g). The content of cytosolic sialidase referred to g fresh tissue increased from birth to 20 days, and slowly decreased thereafter. Till 20 days the content and the developmental trend of the cytosolic enzyme were similar to that of the better known membrane bound sialidase. This latter enzyme, however, reached its maximum at about 60 days of age. The specific activity of the cytosolic sialidase was lower till 10 days of age, higher from 10 to 30 days, and equalled that of the membrane bound enzyme during adult life. Therefore rat forebrain cytosolic and membrane bound sialidases, also from the developmental point of view, behave as different enzymes.
...
PMID:Cytosolic sialidase in developing rat forebrain. 2048 82

The developmental profile of cytosolic sialidase from the nerve ending and the nerve ending-free compartments of rat forebrain was studied from birth to 150 days. Soluble extracts containing the cytosol from nerve endings and nerve ending-free tissue were separately prepared; the recovery of cytosol in the two extracts was followed by assaying lactate-dehydrogenase. In both cytosolic extracts the content of sialidase and lactate-dehydrogenase had a marked and progressive enhancement from the 5th to the 20th day of life and then maintained a constant level through adult life. However the rate of lactate-dehydrogenase and sialidase increase in the two cytosolic compartments was different. Lactate-dehydrogenase increased at a very similar rate in the two cytosols. Instead the rate of sialidase increase was greater in the cytosol from nerve endings from the 5th to the 10th day of life, and, inversely, in the cytosol from nerve ending-free tissue from 10 to 20 days. Between the 5th and 10th day of life the nerve ending cytosol underwent an enrichment of sialidase which was several times higher than that of lactate-dehydrogenase; in the other periods of forebrain development sialidase and lactatedehydrogenase moved in parallel. The variations with age of cytosolic sialidase from the nerve ending-free tissue seemed to follow the overall process of brain development. The nerve ending soluble sialidase would more specifically reflect formation of synaptic junctions in some brain regions in a well defined period of brain maturation.
...
PMID:Cytosolic sialidase from the nerve endings of developing rat forebrain. 2048 90


<< Previous 1 2 3 4 5 6 Next >>

---